Nepal vs Portugal: HIV/AIDS deaths averted by antiretroviral therapy
Nepal
1,348 deaths
in 2024
Portugal
1,420 deaths
in 2024
Nepal rank
69th
Portugal rank
66th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Nepal
- Portugal
How they compare
Portugal currently reports 1,420 deaths against 1,348 deaths in Nepal, a difference of 72 deaths.
That makes Portugal's figure about 1.1 times Nepal's.
Across all 35 years both countries report, Portugal has been ahead every year.
Nepal ranks 69th and Portugal ranks 66th of 157 countries.
Portugal has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Nepal | Portugal | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 125.06 deaths | 125.06 deaths | Portugal |
| 2000s | 175.89 deaths | 1,361 deaths | 1,185 deaths | Portugal |
| 2010s | 1,151 deaths | 1,650 deaths | 499.65 deaths | Portugal |
| 2020s | 1,335 deaths | 1,458 deaths | 122.99 deaths | Portugal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Nepal or Portugal?
- Portugal, at 1,420 deaths against 1,348 deaths in Nepal as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Nepal and Portugal?
- 72 deaths, with Portugal ahead.
- How many years of comparable data are there for Nepal and Portugal?
- 35 years are reported by both, from 1990 to 2024.
- How do Nepal and Portugal rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Nepal ranks 69th and Portugal ranks 66th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.